[go: up one dir, main page]

WO1998047913A3 - Inhibition d'une replication du vih-1 par un analogue peptidique tat du domaine de fixation d'arn - Google Patents

Inhibition d'une replication du vih-1 par un analogue peptidique tat du domaine de fixation d'arn Download PDF

Info

Publication number
WO1998047913A3
WO1998047913A3 PCT/US1998/007533 US9807533W WO9847913A3 WO 1998047913 A3 WO1998047913 A3 WO 1998047913A3 US 9807533 W US9807533 W US 9807533W WO 9847913 A3 WO9847913 A3 WO 9847913A3
Authority
WO
WIPO (PCT)
Prior art keywords
arg
hiv
inhibition
tat
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/007533
Other languages
English (en)
Other versions
WO1998047913A2 (fr
Inventor
Jihong Wang
Stanley Stein
Michael J Leibowitz
Arnold B Rabson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Priority to AU69727/98A priority Critical patent/AU6972798A/en
Publication of WO1998047913A2 publication Critical patent/WO1998047913A2/fr
Publication of WO1998047913A3 publication Critical patent/WO1998047913A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne les composés peptidiques R-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-X-(biotine)-NH2, dans lesquels R est un résidu d'acide carboxylique et X est un résidu de la cystéine ou de la lysine, leurs analogues ou leurs sels biologiquement et pharmaceutiquement acceptables. Lesdits composés contiennent la séquence 9-amino acide issue du domaine de base de la protéine Tat responsable de l'interaction spécifique de TAR ARN, ou son analogue. Le résidu de la cystéine ou de la lysine fournissent un site de liaison pour la biotine qui agit comme un amplificateur de fixation cellulaire. Ces peptides lient fortement et spécifiquement un fragment de TAR ARN (TARΔ), tel que cela a été mesuré dans un dosage de réarrangement par électrophorèse sur gel. Ces peptides inhibent en outre l'expression induite par le gène tat d'un gène marqueur d'une CAT (chloramphénicol acétyl transférase) transfectée de manière stable et liée au VIH-1 à longue répétition terminale dans un dosage cellulaire modèle, mais n'inhibe pas l'expression de CAT induite par phorbol ester, révélant ainsi un mécanisme d'inhibition dépendant de Tat. L'inhibition d'une réplication du VIH-1 après une infection aiguë de cellules MT2 est indiquée par l'absence de formation de syncytium ou de cytotoxycité induite par VIH; elle est également indiquée par la suppression de production d'une transcriptase inverse. Ces résultats montrent que lesdits peptides sont capables de compétir avec le domaine de fixation de TAR ARN de la protéine Tat, et conviennent donc comme agents thérapeutiques dans le traitement du SIDA.
PCT/US1998/007533 1997-04-18 1998-04-16 Inhibition d'une replication du vih-1 par un analogue peptidique tat du domaine de fixation d'arn Ceased WO1998047913A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69727/98A AU6972798A (en) 1997-04-18 1998-04-16 Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84444897A 1997-04-18 1997-04-18
US08/844,448 1997-04-18

Publications (2)

Publication Number Publication Date
WO1998047913A2 WO1998047913A2 (fr) 1998-10-29
WO1998047913A3 true WO1998047913A3 (fr) 1999-01-21

Family

ID=25292742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007533 Ceased WO1998047913A2 (fr) 1997-04-18 1998-04-16 Inhibition d'une replication du vih-1 par un analogue peptidique tat du domaine de fixation d'arn

Country Status (2)

Country Link
AU (1) AU6972798A (fr)
WO (1) WO1998047913A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8912698A (en) 1997-08-19 1999-03-08 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication using d-amino acid peptides
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US20030181367A1 (en) * 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
CA2386231C (fr) * 1999-09-27 2010-09-14 Daniel J. O'mahony Systeme de relargage de medicaments a base d'un peptide de translocation membranaire
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU784264B2 (en) * 2000-02-07 2006-03-02 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
AU2002240312A1 (en) * 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US7803749B2 (en) 2002-01-09 2010-09-28 Xigen Sa Peptide inhibitors of MKK7 kinase binding to insulin binding proteins
US7364842B2 (en) * 2003-05-19 2008-04-29 Irm, Llc Methods of identifying modulators of human retrovirus replication
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
WO2009030254A1 (fr) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
CA2801523C (fr) 2010-07-30 2021-08-03 Curevac Gmbh Complexation d'acides nucleiques avec des composants cationiques reticules par un pont disulfure pour une transfection et une immunostimulation
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012116715A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des nouveaux-nés et des enfants en bas âge
WO2012113413A1 (fr) 2011-02-21 2012-08-30 Curevac Gmbh Composition de vaccin comprenant des acides nucléiques immunostimulateurs complexés et des antigènes emballés avec des conjugués de polyéthylèneglycol/peptide à liaison disulfure
WO2012116714A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des patients âgés
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2013113326A1 (fr) 2012-01-31 2013-08-08 Curevac Gmbh Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834260A4 (fr) 2012-04-02 2016-08-10 Moderna Therapeutics Inc Polynucléotides modifiés pour la production de protéines membranaires
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
MX369469B (es) 2013-08-21 2019-11-08 Curevac Ag Vacuna contra el virus respiratorio sincitial.
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
WO2015149944A2 (fr) 2014-04-01 2015-10-08 Curevac Gmbh Complexe cargo de support polymère à utiliser comme agent immunostimulant ou comme adjuvant
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CN114477459B (zh) * 2022-01-17 2023-02-07 哈尔滨工业大学 一种削减养殖废水中抗生素抗性基因的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007871A1 (fr) * 1990-10-24 1992-05-14 Allelix Biopharmaceuticals Inc. Inhibiteurs de la replication du vih a base de peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007871A1 (fr) * 1990-10-24 1992-05-14 Allelix Biopharmaceuticals Inc. Inhibiteurs de la replication du vih a base de peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOUDHURY, INDRANI ET AL: "Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog", J. ACQUIRED IMMUNE DEFIC. SYNDR. HUM. RETROVIROL. (1998), 17(2), 104-111 CODEN: JDSRET;ISSN: 1077-9450, 1998, XP002080381 *
F. HAMY ET AL.: "An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, no. 8, 15 April 1997 (1997-04-15), WASHINGTON US, pages 3548 - 3553, XP002080382 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells

Also Published As

Publication number Publication date
AU6972798A (en) 1998-11-13
WO1998047913A2 (fr) 1998-10-29

Similar Documents

Publication Publication Date Title
WO1998047913A3 (fr) Inhibition d'une replication du vih-1 par un analogue peptidique tat du domaine de fixation d'arn
Marciniak et al. HIV-1 Tat protein trans-activates transcription in vitro
Mueller et al. Cordycepin analogs of 2', 5'-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase
US6368863B1 (en) Reagents and methods for modulating gene expression through RNA mimicry
Ciminale et al. Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: novel mRNAs and proteins produced by HTLV type I
Clercq New developments in anti-HIV chemotherapy
Zamecnik et al. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.
Shane et al. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV
US6114109A (en) Viral (HIV) growth inhibition
NO178306C (no) Analogifremgangsmåte ved fremstilling av bombesin-antagonistpeptid
FI104252B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidien kemialliseksi syntetisoimiseksi kiinteässä faasissa
AU8292198A (en) Inhibition of hiv-1 replication using oligocarbamate derivatives
Yang et al. Human T cell transcription factor GATA-3 stimulates HIV-1 expression
WO1993012234A1 (fr) Reactifs antiviraux a base de proteines de liaison de l'arn
WO1994015634A9 (fr) Oligopeptide tat et rev utilises pour le traitement du vih
WO1996031217A9 (fr) Inhibition de la replication des retrovirus
US5874564A (en) Reagents and methods for modulating gene expression through RNA mimicry
WO1994015634A1 (fr) Oligopeptide tat et rev utilises pour le traitement du vih
Choudhury et al. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog
Mestre et al. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA
Chandra et al. D‐Penicillamine inhibits transactivation of human immunodeficiency virus type‐1 (HIV‐1) LTR by transactivator protein
Jeyapaul et al. Activity of synthetic tat peptides in human immunodeficiency virus type 1 long terminal repeat-promoted transcription in a cell-free system.
Burzynski et al. Biological active peptides in human urine: III. Inhibitors of the growth of human leukemia, osteosarcoma, and HeLa cells
Fischer et al. The T→ C substitution at-198 of the Aγ-globin gene associated with the British form of HPFH generates overlapping recognition sites for two DNA-binding proteins
Baraz et al. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998546138

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA